KOE · 298380.KQ
ABL Bio Inc.
₩39,200-₩1,800 (-4.39%)
ABL Bio Inc.’s quoted price sits in the lower half of its reported 52-week range, 84.78% below the high.
Loading market information…
KOE · 174900.KQ · KRW
Stock price, earnings
Quote as of Oct 30, 2026, 06:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · KRW. Historical prices are not a forecast.
AbClon Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.72% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow AbClon Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Founded in Seoul, South Korea, in 2010, AbClon Inc. is a biopharmaceutical company engaged in the discovery and development of antibody-based drugs, with operations spanning South Korea and Sweden. The firm's developmental pipeline encompasses therapies derived from distinct technological platforms: the NEST platform addresses breast and gastric cancers; the AffiMab platform targets colon cancer and various autoimmune conditions; and the CAR-T platform is engineered for hematologic and ovarian cancers.
Latest available per-share figures in KRW. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:39 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₩39,200-₩1,800 (-4.39%)
ABL Bio Inc.’s quoted price sits in the lower half of its reported 52-week range, 84.78% below the high.
₩92,300-₩4,900 (-5.04%)
Peptron, Inc.’s quoted price sits in the lower half of its reported 52-week range, 76.48% below the high.
₩106,100-₩9,100 (-7.9%)
Voronoi, Inc.’s quoted price sits in the lower half of its reported 52-week range, 71.74% below the high.
₩12,110-₩510 (-4.04%)
Onconic Therapeutics’s quoted price sits in the lower half of its reported 52-week range, 58.1% below the high.
₩6,730-₩210 (-3.03%)
GI Innovation, Inc.’s quoted price sits in the lower half of its reported 52-week range, 67.88% below the high.
₩15,320-₩490 (-3.1%)
Orum Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 89.55% below the high.
₩2,020-₩40 (-1.94%)
SillaJen, Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.59% below the high.
₩4,020-₩135 (-3.25%)
Prestige BioPharma Limited’s quoted price sits in the lower half of its reported 52-week range, 71.53% below the high.
